Eli Lilly Posts Strong Q2 Earnings but GLP-1 Pill Disappointment Weighs on Stock
Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter ...
Zepbound and Mounjaro Drive U.S. Sales, Yet Orforglipron Trial Results Raise Investor Concerns Eli Lilly (LLY) delivered a solid second-quarter ...
Next-Gen BVA Device Promises Faster, More Accurate Fluid Management for Millions of Patients Daxor Corporation (DXR), a global leader in ...
Cosmetics giant sees 30% profit drop as China duties weigh on bottom line, even as revenue and product innovation remain ...
Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks Hims & Hers Health (HIMS) stock ...
AI-driven growth, strong U.S. contracts, and Trump’s cost-cutting push propel Palantir into the top 10 U.S. tech companies by market ...
New stock grant aims to secure Musk’s commitment as legal battle over $56 billion 2018 pay package continues Tesla’s (TSLA) ...
Electric air taxi pioneer Joby expands passenger operations as Blade spins off medical transport arm into new public company Blade ...
Record Automotive Revenue and $3.8 Billion Returned to Shareholders Highlight Robust Quarter Qualcomm (QCOM) delivered solid third-quarter fiscal 2025 results, ...
Why Investors Are Doubling Down on These Market Leaders in AI and Cloud Computing Advanced Micro Devices (AMD) and Amazon ...
Deal includes CBS, Nickelodeon, and Paramount Pictures; DEI policies rejected as scrutiny mounts The Federal Communications Commission (FCC) on Thursday ...
© 2024 All Rights Reserved: STOXPO.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More
In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information
Do you really wish to opt-out?